Accessing unfunded cancer drugs in publicly funded hospitals

The Lancet Oncology

Volumn 10, Issue 4, 2009, Pages 306-307

  Chafe, Roger ^a   Dhalla, Irfan A ^b   Dobrow, Mark ^a   Sullivan, Terrence ^a  

^a CANCER CARE ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; DRUG COST; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUBLIC HOSPITAL; QUALITY OF LIFE; REIMBURSEMENT; SOLID TUMOR;

ENGLAND; FINANCING, GOVERNMENT; HOSPITALS, PUBLIC; HUMANS; LEGISLATION, DRUG; NATIONAL HEALTH PROGRAMS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 63249118372     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70039-7     Document Type: Letter

References (4)

1. Richards M. Improving access to medicines for NHS patients. London: Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publicati onsPolicyAndGuidance/DH_089927 (accessed March 10, 2009).
2. Report of the provincial working group on the delivery of oncology medications for private payment in Ontario hospitals, Toronto: Cancer Care Ontario. http://www.cancercare.on.ca/documents/Report_on_Unfunded_Cancer_Drugs.pd f (accessed March 10, 2009).
3. Chung C. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13 (2008) 725-732
4. Flood C., and Archibald T. The illegality of private health care in Canada. CMAJ 164 (2001) 825-830